{"product_id":"elekta-bcg-matrix","title":"Elekta Boston Consulting Group Matrix","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eElekta's BCG Matrix assesses product units in Stars, Cash Cows, Question Marks, and Dogs, optimizing investment strategies. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003ePrintable summary optimized for A4 and mobile PDFs, ensuring clear communication of business unit strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eElekta BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Elekta BCG Matrix preview mirrors the final product you'll get. It's the complete, ready-to-use document designed for easy analysis and presentation, immediately available upon purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eBCG Matrix Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eElekta’s BCG Matrix reveals a snapshot of its product portfolio. Stars represent promising areas, while Cash Cows fuel growth. Question Marks need strategic focus; Dogs require careful consideration. This preview is just a starting point. Get the full BCG Matrix report for in-depth analysis and strategic recommendations to guide your investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta Unity MR-Linac\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta Unity, a star in Elekta's portfolio, is the first high-field MR-Linac. This innovation merges MRI with radiation therapy, enabling real-time adaptive treatments. In 2024, its revenue contribution is crucial, boosting Elekta's market presence. The technology's precision attracts significant investment, fueling growth. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta Evo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta Evo, launched in 2024, is a \"Star\" in Elekta's BCG Matrix. This AI-powered system offers workflow automation. It provides online and offline adaptive radiotherapy. Customer feedback in Q3 2024\/25 was very positive. Its market share is expected to increase by 15% in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta ONE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta ONE, a star in Elekta's portfolio, is a recent oncology software innovation. It enhances user experience while maintaining treatment quality, integrating with Elekta Evo. In 2024, Elekta's software revenue increased, reflecting ONE's growing impact. Recognized as 'Best in KLAS,' Elekta ONE offers a comprehensive application suite. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVersa HD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElekta's Versa HD linear accelerator is positioned as a Star in the BCG Matrix, indicating high market growth and a strong market share. This platform is favored for its high-dose-rate beam delivery and advanced treatment capabilities, crucial for modern radiotherapy. It excels in treating various cancers, including brain metastases, showcasing its versatility. In 2024, Elekta's oncology solutions, including Versa HD, contributed significantly to its revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eVersa HD is a key product for Elekta's oncology segment.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eOffers advanced treatment modalities and motion management.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eBrain metastases solutions are a key feature.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eElekta's oncology solutions drive revenue growth.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta Esprit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElekta Esprit, the newest Leksell Gamma Knife, is a Star in Elekta's BCG matrix, indicating high market share and growth potential. It received FDA clearance in October 2022, marking a significant advancement in radiosurgery. This platform offers faster treatment planning and improved accuracy. Elekta's neuroscience solutions, including Esprit, are expected to contribute significantly to the company's revenue in 2024. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eFDA clearance in October 2022.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on brain disorder treatments.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eExpectation of revenue increase in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta's Stellar Products: Revenue Drivers Unveiled\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta's \"Stars\" represent high-growth, high-share products driving revenue. Elekta Unity and Evo, launched in 2024, are key innovations. Versa HD and Esprit continue to strengthen Elekta's market position.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2024 Revenue Contribution (Est.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eElekta Unity\u003c\/td\u003e\n\u003ctd\u003eMR-Linac for adaptive treatments\u003c\/td\u003e\n\u003ctd\u003eSignificant, driving market presence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElekta Evo\u003c\/td\u003e\n\u003ctd\u003eAI-powered workflow automation\u003c\/td\u003e\n\u003ctd\u003eExpected 15% market share increase in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElekta ONE\u003c\/td\u003e\n\u003ctd\u003eOncology software suite\u003c\/td\u003e\n\u003ctd\u003eIncreased software revenue in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVersa HD\u003c\/td\u003e\n\u003ctd\u003eLinear accelerator, advanced treatments\u003c\/td\u003e\n\u003ctd\u003eKey revenue contributor in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElekta Esprit\u003c\/td\u003e\n\u003ctd\u003eLeksell Gamma Knife\u003c\/td\u003e\n\u003ctd\u003eExpected revenue increase in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLinear Accelerators (Linacs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta's linear accelerators (linacs) are a key component of its \"Cash Cows\" in the BCG Matrix. Elekta has a substantial installed base of over 7,300 linacs worldwide. The global radiation therapy market, fueled by tech advancements, is projected to grow, thus ensuring stable revenue. Elekta's linacs, like Versa HD, are major revenue contributors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMOSAIQ Oncology Information System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta's MOSAIQ is a key oncology information system, managing patient data and treatment workflows. It supports various cancer treatments, including radiation therapy. A significant deal in Mexico highlights its market presence. MOSAIQ integrates with the Monaco treatment planning system, enhancing its functionality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrachytherapy Applicators and Afterloaders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrachytherapy applicators and afterloaders are key in HDR procedures, enhancing precision. This segment was the highest revenue-generating in the global breast cancer brachytherapy market in 2024. The market's expansion reflects the need for accurate radiation delivery. Sales in 2024 reached $2.3 billion, showing strong demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta Care Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eElekta Care Services, a significant cash cow for Elekta, focuses on customer satisfaction through services, learning, and community support. These services include Elekta Care Support, Elekta Care 360, Elekta Care Learning, and Elekta Care Community, all designed to boost system uptime and performance. Although specific 2024 revenue figures are not yet available, service revenue typically contributes substantially to Elekta's overall income. In 2023, Elekta's service revenue was a significant portion of total revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eElekta Care contributes to customer retention.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eServices include Support, 360, Learning, and Community.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThese services aim to increase system uptime and performance.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eService revenue is a key part of Elekta's income.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTreatment Planning Systems (e.g., Monaco)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eElekta's Monaco treatment planning systems are crucial for radiation therapy, generating steady revenue. These systems are integrated into major agreements and are consistently updated with new features. The acquisition of Philips' Pinnacle TPS patent portfolio strengthens Elekta's market standing. This segment provides a reliable income source, essential for consistent performance. In 2024, this area saw a 5% revenue increase.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSteady Revenue:\u003c\/strong\u003e Treatment planning systems provide a stable income.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eContinuous Updates:\u003c\/strong\u003e New features keep the systems competitive.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Acquisition:\u003c\/strong\u003e Philips' patent portfolio boosts Elekta.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Performance:\u003c\/strong\u003e This segment grew by 5% in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable Revenue Streams: The Company's Key Offerings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta's \"Cash Cows\" provide stable revenue through established products and services. These include linacs with over 7,300 installations, and MOSAIQ, crucial for managing patient data. Brachytherapy and Care Services also drive revenue, with services showing strong contributions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\/Service\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2024 Revenue (Estimate)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLinacs\u003c\/td\u003e\n\u003ctd\u003eRadiation therapy machines\u003c\/td\u003e\n\u003ctd\u003eSignificant, based on installed base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMOSAIQ\u003c\/td\u003e\n\u003ctd\u003eOncology information system\u003c\/td\u003e\n\u003ctd\u003eSteady, with market presence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrachytherapy\u003c\/td\u003e\n\u003ctd\u003ePrecision radiation delivery\u003c\/td\u003e\n\u003ctd\u003e$2.3 billion market in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElekta Care Services\u003c\/td\u003e\n\u003ctd\u003eCustomer support and services\u003c\/td\u003e\n\u003ctd\u003eSubstantial, service revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Brachytherapy Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta's legacy brachytherapy products, facing competition, might be \"dogs.\" Although the brachytherapy market is projected to hit USD 1.88 billion by 2035, older tech could lose share. Newer methods often offer advantages. Competitors' advancements further challenge these older offerings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProducts with Declining Market Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDogs are products in low-growth markets with low market share. Elekta's U.S. and China net sales were hit by lower volumes in 2024. Minimizing these products is crucial. For example, in Q1 2024, Elekta reported a decline in order intake. Products in this category are struggling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutdated Software Versions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOutdated software, not part of Elekta ONE, fits the \"dog\" category. These older versions may lack competitiveness compared to newer, integrated solutions. Maintaining software relevance requires regular updates and integration. In 2024, approximately 15% of Elekta's revenue came from older, non-integrated systems, signaling a need for strategic upgrades. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProducts Facing Intense Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElekta's products, especially those competing with the likes of Varian and Siemens Healthineers, could be classified as \"dogs\" if they struggle to maintain market share. Healthineers represents a significant competitive threat, and Elekta's performance hinges on Unity's continued adoption and its ability to fend off rivals. The company's financial results reflect this dynamic. For example, in fiscal year 2023\/2024, Elekta's order intake decreased by 1% at constant exchange rates, which shows the pressure. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eOrder intake decreased by 1% at constant exchange rates in fiscal year 2023\/2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHealthineers poses a formidable competitive challenge.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eUnity's adoption is crucial for Elekta's success.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProducts with High Maintenance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDogs in Elekta's portfolio are products with high maintenance costs and low returns. High equipment costs, need for skilled staff, and regulatory hurdles hinder profitability. Innovation should target cost reduction, user-friendliness, and integration. In 2024, Elekta's R\u0026amp;D spending was 12% of revenue, focusing on these areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh Maintenance Costs:\u003c\/strong\u003e Products with significant upkeep expenses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLow Returns:\u003c\/strong\u003e Generating minimal profit or revenue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImpact of Costs:\u003c\/strong\u003e Equipment, personnel, regulatory factors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovation Focus:\u003c\/strong\u003e Reduce costs, improve ease of use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta's Brachytherapy: Low Returns \u0026amp; High Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta's \"dogs\" struggle in low-growth markets with low market share. Older brachytherapy products face competition, potentially falling into this category. These products suffer from high maintenance and low returns, impacted by equipment costs and regulatory hurdles. In fiscal year 2023\/2024, order intake decreased by 1% at constant exchange rates, reflecting these challenges.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFeature\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Share\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eAffected by competitors like Varian and Siemens.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancials\u003c\/td\u003e\n\u003ctd\u003eLow Returns\u003c\/td\u003e\n\u003ctd\u003eOrder intake decreased by 1% in fiscal year 2023\/2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaintenance\u003c\/td\u003e\n\u003ctd\u003eHigh Costs\u003c\/td\u003e\n\u003ctd\u003eEquipment, personnel, and regulatory expenses.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProton Therapy Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProton therapy is a burgeoning field within radiation therapy, offering highly targeted cancer treatment. Elekta's expansion in proton therapy solutions could tap into this growth; the global proton therapy market was valued at $728 million in 2024. This technology, like proton beam therapy, presents significant, yet still largely untapped, potential for Elekta. Consider that the market is projected to reach $1.4 billion by 2030.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Driven Adaptive Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAI-driven adaptive therapy instantly refines plans for enhanced precision and workflow efficiency. Elekta's investment in AI, like Elekta Evo, offers online and offline adaptive radiotherapy. In 2024, the global radiotherapy market was valued at $6.8 billion. Further development and marketing could elevate these AI solutions to \"star\" status. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeterinary Radiation Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeterinary radiation therapy presents a niche market with growth possibilities, particularly for companies like Elekta. Elekta could diversify its revenue streams by expanding its offerings in this specialized area. While Elekta already has products in veterinary radiation therapy, further investment could increase market share. The global veterinary oncology market was valued at $305.2 million in 2024, projected to reach $475.1 million by 2030.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eElekta's expansion in emerging markets is a key element of its growth strategy. These markets have a lower patient population per installed base compared to developed regions, presenting a significant opportunity. Elekta's ACCESS 2025 strategy directly targets low- and middle-income geographies, aiming to capitalize on this. Strategic focus on underpenetrated markets could transform them into \"stars\" within the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eACCESS 2025 strategy targets low- and middle-income countries.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEmerging markets offer significant growth potential.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on underpenetrated markets.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePatient population per installed base is lower.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration with Theranostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eElekta could benefit from integrating theranostics, a precision medicine approach using diagnostic biomarkers with targeted therapeutics. Collaborating with theranostics specialists could enhance Elekta's personalized cancer care solutions. GE HealthCare's partnership with Mayo Clinic highlights the potential of this area. This could lead to more effective and tailored cancer treatments. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eTheranostics combines diagnostics and therapy for personalized cancer treatment.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePartnerships with theranostics companies could boost Elekta's offerings.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGE HealthCare's ventures signal the growing importance of theranostics.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis integration could improve treatment outcomes for patients.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlocking Growth: From Question Marks to Stars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta's \"Question Marks\" are areas with high potential but uncertain returns in the BCG Matrix.\u003c\/p\u003e\n\u003cp\u003eThese include proton therapy, AI-driven solutions, veterinary radiation therapy, expansion into emerging markets, and theranostics integration.\u003c\/p\u003e\n\u003cp\u003eSuccess depends on strategic investment and market execution to transform these into \"Stars.\"\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\/Strategy\u003c\/th\u003e\n\u003cth\u003eMarket Status\u003c\/th\u003e\n\u003cth\u003eElekta's Focus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProton Therapy\u003c\/td\u003e\n\u003ctd\u003eBurgeoning; $728M (2024)\u003c\/td\u003e\n\u003ctd\u003eExpansion in proton therapy solutions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI-Driven Solutions\u003c\/td\u003e\n\u003ctd\u003eGrowing; $6.8B (2024) radiotherapy market\u003c\/td\u003e\n\u003ctd\u003eInvestment in AI, adaptive therapy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeterinary RT\u003c\/td\u003e\n\u003ctd\u003eNiche; $305.2M (2024)\u003c\/td\u003e\n\u003ctd\u003eExpanding offerings in veterinary oncology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003ch2\u003eBCG Matrix \u003cspan style=\"color: #FB9C46;\"\u003eData Sources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThis Elekta BCG Matrix is built using public financial reports, market analysis data, and competitive intelligence for actionable insights. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Data-Sources.svg\" alt=\"Data Sources\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56070344245632,"sku":"elekta-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/elekta-bcg-matrix.png?v=1749419222","url":"https:\/\/swotanalysistemplates.com\/products\/elekta-bcg-matrix","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}